Read my take on promising new data from HIVR4P 2021 on monthly oral islatravir and injectable cabotegravir as long-acting PrEP options.
Read my take on promising new data from HIVR4P // Virtual 2021 on broadly neutralizing HIV antibody immunoprophylaxis and multipurpose prevention technologies under investigation for HIV prevention.
In this downloadable slideset, CCO’s expert faculty members summarize key studies from this important conference, including clinical data on new PrEP options, implementation strategies, multipurpose prevention technologies, and an emerging treatment.
In this Webcast, Dr. Kenneth Mayer summarizes key studies from this important conference, including clinical data on new/emerging PrEP options, implementation strategies, and multipurpose prevention technologies.
Hear insights from Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, on some of the most important new data reported at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), including results from studies evaluating novel approaches to HIV prevention such as broadly neutralizing antibodies, long-acting injectable and oral ARVs, implantable options, multipurpose prevention strategies, and key aspects of PrEP implementation